BDNF augmentation reverses cranial radiation therapy-induced cognitive decline and neurodegenerative consequences

Acta Neuropathol Commun. 2024 Dec 18;12(1):190. doi: 10.1186/s40478-024-01906-9.

Abstract

Cranial radiation therapy (RT) for brain cancers is often associated with the development of radiation-induced cognitive dysfunction (RICD). RICD significantly impacts the quality of life for cancer survivors, highlighting an unmet medical need. Previous human studies revealed a marked reduction in plasma brain-derived neurotrophic factor (BDNF) post-chronic chemotherapy, linking this decline to a substantial cognitive dysfunction among cancer survivors. Moreover, riluzole (RZ)-mediated increased BDNF in vivo in the chemotherapy-exposed mice reversed cognitive decline. RZ is an FDA-approved medication for ALS known to increase BDNF in vivo. In an effort to mitigate the detrimental effects of RT-induced BDNF decline in RICD, we tested the efficacy of RZ in a cranially irradiated (9 Gy) adult mouse model. Notably, RT-exposed mice exhibited significantly reduced hippocampal BDNF, accompanied by increased neuroinflammation, loss of neuronal plasticity-related immediate early gene product, cFos, and synaptic density. Spatial transcriptomic profiling comparing the RT + Vehicle with the RT + RZ group showed gene expression signatures of neuroprotection of hippocampal excitatory neurons post-RZ. RT-exposed mice performed poorly on learning and memory, and memory consolidation tasks. However, irradiated mice receiving RZ (13 mg/kg, drinking water) for 6-7 weeks showed a significant improvement in cognitive function compared to RT-exposed mice receiving vehicle. Dual-immunofluorescence staining, spatial transcriptomics, and biochemical assessment of RZ-treated irradiated brains demonstrated preservation of synaptic integrity and mature neuronal plasticity but not neurogenesis and reduced neuroinflammation concurrent with elevated BDNF levels and transcripts compared to vehicle-treated irradiated brains. In summary, oral administration of RZ represents a viable and translationally feasible neuroprotective approach against RICD.

Keywords: BDNF; Cognitive function; Cranial radiation therapy; Neuroinflammation; Neuronal plasticity; Riluzole.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain-Derived Neurotrophic Factor* / genetics
  • Brain-Derived Neurotrophic Factor* / metabolism
  • Cognitive Dysfunction* / etiology
  • Cognitive Dysfunction* / metabolism
  • Cranial Irradiation* / adverse effects
  • Female
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Hippocampus / radiation effects
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neurodegenerative Diseases / radiotherapy
  • Neuroprotective Agents / pharmacology

Substances

  • Brain-Derived Neurotrophic Factor
  • Bdnf protein, mouse
  • Neuroprotective Agents